Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MTOR | P42345 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363487 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL18870816 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL207772 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL1230711 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL5697575 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL2583898 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL16805415 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL4286246 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL21423108 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL30694436 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240191231-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2024-06-13 | — | — | US | claimed |
| WO-2023154964-A1 | METHODS AND COMPOSITIONS FOR TARGETING EFEMP1 | ALLOY THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | UNIVERSITY OF MASSACHUSETTS | 2022-04-14 | — | — | US | claimed |
| US-20220090071-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2022-03-24 | — | — | US | claimed |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2021-10-05 | — | — | US | claimed |
| US-11053503-B2 | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition | KCL THERAPEUTICS, INC | 2021-07-06 | — | — | US | claimed |
| WO-2021117122-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR LYSOSOMAL ACID LIPASE DEFICIENCY SYNDROME | 株式会社リボルナバイオサイエンス | 2021-06-17 | — | — | WO | claimed |
| US-20190292540-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2019-09-26 | — | — | US | claimed |
| US-10266822-B2 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2019-04-23 | — | — | US | claimed |
| US-20190085328-A1 | IN VIVO SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | UNIVERSITY OF MASSACHUSETTS | 2019-03-21 | — | — | US | claimed |
| EP-0653439-B1 | Stabilized oligonucleotids and the use thereof | AVENTIS PHARMA GMBH (DE) | 2004-04-28 | — | — | EP | claimed |
| WO-2004029212-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2004-04-08 | — | — | WO | claimed |
| EP-0983290-B1 | METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS | MORPHOCHEM AG (DE) | 2004-03-03 | — | — | EP | claimed |
| JP-2002500643-A | — | — | 2002-01-08 | — | — | JP | claimed |
| EP-0594667-B1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 2001-09-19 | — | — | EP | claimed |
| EP-0350287-B1 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | CHIMERIX INC (US) | 2000-09-27 | — | — | EP | claimed |
| EP-0983290-A1 | METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS | Morphochem AG (DE) | 2000-03-08 | — | — | EP | claimed |
| WO-1998051697-A2 | METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS | MORPHOCHEM AG (DE) | 1998-11-19 | — | — | WO | claimed |
| EP-0653439-A2 | Stabilized oligonucleotids and the use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-17 | — | — | EP | claimed |
| EP-0595133-A2 | Prodrugs, their preparation and use as medicaments | BEHRINGWERKE Aktiengesellschaft (DE) | 1994-05-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085328-A1 | IN VIVO SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | AGO2, SNRPE, NSUN2 | LMNA 2205/4885MTOR 2815/4885ALDH1A1 2569/4885 |
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | SNRPE, AGO2, NSUN2 | LMNA 2786/4885MTOR 3352/4885ALDH1A1 2194/4885 |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | SNRPE, AGO2, NSUN2 | LMNA 2786/4885MTOR 3352/4885ALDH1A1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.